Published in Lab Invest on April 01, 1984
Bunyamwera bunyavirus nonstructural protein NSs is a nonessential gene product that contributes to viral pathogenesis. Proc Natl Acad Sci U S A (2001) 2.63
La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol (2007) 1.90
Deduced consensus sequence of Sindbis virus strain AR339: mutations contained in laboratory strains which affect cell culture and in vivo phenotypes. J Virol (1996) 1.88
Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. J Virol (1999) 1.62
Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention. J Virol (1996) 1.50
Arboviral encephalitides: transmission, emergence, and pathogenesis. J Neuroimmune Pharmacol (2010) 1.24
Epidemiology, molecular virology and diagnostics of Schmallenberg virus, an emerging orthobunyavirus in Europe. Vet Res (2013) 1.20
Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies. J Virol (1995) 1.13
An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function. J Virol (1985) 1.12
A genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatching. Genes Dev (2013) 1.09
Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066-1087) as the fusion peptide. Virology (2006) 1.06
Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment. J Virol (1991) 1.03
Virulence of La Crosse virus is under polygenic control. J Virol (1986) 1.02
Polygenic control of neuroinvasiveness in California serogroup bunyaviruses. J Virol (1993) 0.98
Visualizing production of beta interferon by astrocytes and microglia in brain of La Crosse virus-infected mice. J Virol (2012) 0.97
La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol J (2008) 0.96
Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys. Virol J (2011) 0.92
Typing of LaCrosse, snowshoe hare, and Tahyna viruses by analyses of single-strand conformation polymorphisms of the small RNA segments. J Clin Microbiol (1995) 0.92
Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes. Virol J (2007) 0.92
Neuroattenuated bunyavirus variant: derivation, characterization, and revertant clones. J Virol (1990) 0.91
Orthobunyavirus entry into neurons and other mammalian cells occurs via clathrin-mediated endocytosis and requires trafficking into early endosomes. J Virol (2012) 0.89
La Crosse virus (LACV) Gc fusion peptide mutants have impaired growth and fusion phenotypes, but remain neurotoxic. Virology (2010) 0.85
Differentiation of neurons restricts Arbovirus replication and increases expression of the alpha isoform of IRF-7. J Virol (2014) 0.82
Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease. J Virol (2014) 0.81
Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice. J Neuroinflammation (2017) 0.75
The Young Men's Survey: methods for estimating HIV seroprevalence and risk factors among young men who have sex with men. Public Health Rep (1996) 8.27
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature (1972) 4.08
Equity in the finance of health care: some international comparisons. J Health Econ (1992) 3.43
Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol (2000) 2.97
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science (1991) 2.77
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. II. Adoptive immunization of virus carriers. J Exp Med (1972) 2.68
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol (1979) 2.58
Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg (1988) 2.57
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
Immunopathogenesis of acute central nervous system disease produced by lymphocytic choriomeningitis virus. I. Cyclophosphamide-mediated induction by the virus-carrier state in adult mice. J Exp Med (1972) 2.37
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry (1994) 2.25
Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide. Nature (1968) 2.16
The genetics of susceptibility to multiple sclerosis. Epidemiol Rev (1982) 2.00
Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A (1993) 1.96
Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest (1976) 1.96
Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med (1996) 1.90
Calpain regulates actin remodeling during cell spreading. J Cell Biol (1998) 1.90
The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol (1979) 1.87
Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses (2001) 1.81
Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.80
Immunosuppression and experimental virus infection of the nervous system. Adv Virus Res (1970) 1.79
Human exposure to SV40: review and comment. Am J Epidemiol (1976) 1.77
Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol (1993) 1.67
Lymphocytic choriomeningitis virus: pathogenesis of acute central nervous system disease. Fed Proc (1972) 1.66
Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol (2001) 1.66
Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol (1990) 1.65
Fatal Japanese encephalitis virus infection in immunosuppresed spider monkeys. Clin Exp Immunol (1970) 1.61
The effect of soft cervical collars on persistent neck pain in patients with whiplash injury. Acad Emerg Med (1996) 1.61
Equity in the delivery of health care: some international comparisons. J Health Econ (1992) 1.60
Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol (1982) 1.60
Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J Immunol (2001) 1.52
Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis (1974) 1.51
Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention. J Virol (1996) 1.50
Lymphocytic choriomeningitis. Pathogenesis. Prog Med Virol (1974) 1.47
Central nervous system immunity in mice infected with theiler's virus. I. Local neutralizing antibody response. J Infect Dis (1978) 1.46
WHO Neuropsychiatric AIDS study, cross-sectional phase I. Study design and psychiatric findings. Arch Gen Psychiatry (1994) 1.46
Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. Lab Invest (1976) 1.42
Eradication of poliomyelitis in the United States. Rev Infect Dis (1983) 1.42
Experimental infection of monkeys with Langat virus II. Turnover of circulating virus, 1967. Rev Med Virol (2000) 1.42
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun (1997) 1.41
Replication of type 1 human immunodeficiency viruses containing linker substitution mutations in the -201 to -130 region of the long terminal repeat. J Virol (1993) 1.37
Experimental encephalitis following peripheral inoculation of West Nile virus in mice of different ages. J Hyg (Lond) (1970) 1.34
Pathogenesis of West Nile Virus encepahlitis in mice and rats. II. Virus multiplication, evolution of immunofluorescence, and development of histological lesions in the brain. Am J Epidemiol (1967) 1.31
An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol (1984) 1.30
Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology (1986) 1.29
Pathogenesis of West Nile Virus encephalitis in mice and rats. 1. Influence of age and species on mortality and infection. Am J Epidemiol (1967) 1.28
Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology (1993) 1.27
Organization of the middle RNA segment of snowshoe hare Bunyavirus. Virology (1988) 1.26
Histological studies of the monkey neurovirulence of group B arboviruses. I. A semiquantitative grading scale. Am J Epidemiol (1965) 1.24
Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures. J Infect Dis (1994) 1.24
Characterization of monoclonal antibodies against the G1 and N proteins of LaCrosse and Tahyna, two California serogroup bunyaviruses. Virology (1982) 1.23
Pathogenesis of cerebellar hypoplasia produced by lymphocytic choriomeningitis virus infection of neonatal rats. 1. Evolution of disease following infection at 4 days of age. J Neuropathol Exp Neurol (1973) 1.21
The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells. J Immunol (1978) 1.19
Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology (1988) 1.18
Mismatched wear couple zirconium oxide and aluminum oxide in total hip arthroplasty. J Arthroplasty (2001) 1.18
Acute rabies death mediated by antibody. Nature (1981) 1.17
Completion of the La Crosse virus genome sequence and genetic comparisons of the L proteins of the Bunyaviridae. Virology (1995) 1.16
HTLV-I-associated myelopathy associated with blood transfusion in the United States: epidemiologic and molecular evidence linking donor and recipient. Neurology (1991) 1.14
Linkage of myostatin pathway genes with knee strength in humans. Physiol Genomics (2004) 1.14
Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies. J Virol (1995) 1.13
Expression of the La Crosse M segment proteins in a recombinant vaccinia expression system mediates pH-dependent cellular fusion. Virology (1993) 1.13
Comprehensive survey of developmental genes in the pea aphid, Acyrthosiphon pisum: frequent lineage-specific duplications and losses of developmental genes. Insect Mol Biol (2010) 1.13
Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol (1990) 1.12
An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function. J Virol (1985) 1.12
Heterotopic cerebellar granule cells following administration of cyclophosphamide to suckling rats. Brain Res (1969) 1.11
Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet (2001) 1.10
Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop. Virology (1994) 1.09
Immunosuppression: a means to assess the role of the immune response in acute virus infections. Fed Proc (1972) 1.09
Molecular determinants of the virulence and infectivity of California serogroup bunyaviruses. Annu Rev Microbiol (1993) 1.08
Antigenic drift in visna: virus variation during long-term infection of Icelandic sheep. J Gen Virol (1983) 1.07
Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. Clin Microbiol Infect (2004) 1.07
Experimental visna in Icelandic sheep: the prototype lentiviral infection. Rev Infect Dis (1985) 1.06
Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment. J Virol (1991) 1.03
Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem (1994) 1.03
Virulence of La Crosse virus is under polygenic control. J Virol (1986) 1.02
Species identification of cyst and root-knot nematodes from potato by electrophoresis of individual females. Electrophoresis (1995) 1.02
A G1 glycoprotein epitope of La Crosse virus: a determinant of infection of Aedes triseriatus. Science (1987) 1.02
Histological studies of the monkey neurovirulence of group B arboviruses. II. Selection of indicator centers. Am J Epidemiol (1966) 1.02
The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol (1995) 1.02
The large viral RNA segment of California serogroup bunyaviruses encodes the large viral protein. J Gen Virol (1989) 1.01
Effect of antilymphocyte serium on tacaribe virus infection in infant mice. Infect Immun (1971) 1.01